Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054262 · ClinicalTrials.gov registry record · Phase 2

T900607 in Treating Patients With Unresectable Liver Cancer

A Phase 2 study, sponsored by University Hospitals Seidman Cancer Center.

Completed
Registry status
Phase 2
Development phase

NCT00054262: Completed Phase 2 study, sponsored by University Hospitals Seidman Cancer Center.

NCT00054262 is a Phase 2 study that has completed, run by University Hospitals Seidman Cancer Center. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054262, a Phase 2 study, has completed, sponsored by University Hospitals Seidman Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable liver cancer.

Interventions

  • DRUG T900607

Trial Details

FieldValue
Start Date 2002-11
Est. Completion 2010-09
Phase Phase 2

What the finished NCT00054262 record still lists

NCT00054262 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which T900607 is the first listed.

NCT00054262 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00054262 about?

NCT00054262 is a clinical study titled "T900607 in Treating Patients With Unresectable Liver Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable liver cancer.

What is the current status of trial NCT00054262?

This trial is currently completed. It is a Phase 2 study. The study started on 2002-11. Estimated completion is 2010-09.

What interventions are being tested in trial NCT00054262?

The interventions under investigation include: T900607 (DRUG).

Who is sponsoring clinical trial NCT00054262?

This trial is sponsored by University Hospitals Seidman Cancer Center, which has 2 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00054262, the US trial registry maintained by the National Library of Medicine. NCT00054262 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.